Inhaled liposomal amphotericin-B as a prophylactic treatment for COVID-19-associated pulmonary aspergillosis/aspergillus tracheobronchitis

COVID-19-associated pulmonary aspergillosis (CAPA) is a recently described complication of severe Coronavirus Disease of 2019 and is associated with increased morbidity and mortality [1, 2]. Also Aspergillus tracheobronchi-tis (AT) is common in this disease. We reported already during the first pandemic wave that CAPA/AT was frequently encountered in our 31-bed mixed ICU (Zieken-huisNetwerk Antwerpen, Belgium) where we